Aptar Pharma will co-develop and promote i2c Pharmaceutical Services’ Respitab MDI technology, the two companies have announced. The Respitab system involves formulating the drug as a tablet that can be easily dispensed into an MDI canister; the tablet is then dissolved or dispersed when the can is filled with propellant.
According to the announcement, Aptar will focus especially on the use of Respitab in conjunction with lower global warming potential propellants. Aptar Pharma subsidiary Nanopharm offers complete contract development services for MDIs in partnership with Sciarra Laboratories.
i2c Pharmaceutical Services Chief Scientific Officer Glyn Taylor commented, “We are excited by this partnership with Aptar Pharma which brings together substantial synergies to provide a lower GWP product range to patients in the pMDI format, the most popular inhaler type across the globe.”
Aptar Pharma VP, Global Pulmonary Category, Howard Burnett said, “We are pleased to partner with i2c on this novel technology which brings many benefits to the filling of metered dose inhalers. This development further enhances Aptar Pharma’s industry- leading portfolio of devices, which, combined with our broad spectrum of Aptar Pharma Services, allows us to offer end-to-end support to our clients and partners.”
Read the Aptar Pharma and i2c Pharmaceutical Services press release.
